Metropolitan Life Insurance Co. NY cut its holdings in Anika Therapeutics Inc (NASDAQ:ANIK) by 50.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,141 shares of the biotechnology company’s stock after selling 5,276 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Anika Therapeutics were worth $277,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in ANIK. SG Americas Securities LLC purchased a new stake in shares of Anika Therapeutics in the 3rd quarter worth about $118,000. JPMorgan Chase & Co. grew its position in shares of Anika Therapeutics by 2,781.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,859 shares of the biotechnology company’s stock worth $982,000 after buying an additional 16,274 shares during the period. Wells Fargo & Company MN grew its position in shares of Anika Therapeutics by 25.0% in the 3rd quarter. Wells Fargo & Company MN now owns 209,928 shares of the biotechnology company’s stock worth $12,176,000 after buying an additional 42,015 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Anika Therapeutics by 2.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 895,600 shares of the biotechnology company’s stock worth $51,945,000 after buying an additional 17,594 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. grew its position in shares of Anika Therapeutics by 415.7% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,194 shares of the biotechnology company’s stock worth $359,000 after buying an additional 4,993 shares during the period. 84.10% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have recently weighed in on the stock. Barrington Research downgraded shares of Anika Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, February 23rd. BidaskClub cut shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. ValuEngine cut shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, April 12th. Sidoti initiated coverage on shares of Anika Therapeutics in a research note on Friday, January 26th. They issued a “buy” rating on the stock. Finally, Zacks Investment Research cut shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, February 26th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $62.50.
Shares of Anika Therapeutics stock opened at $45.13 on Friday. The stock has a market capitalization of $671.35, a P/E ratio of 23.03, a PEG ratio of 2.90 and a beta of 1.73. Anika Therapeutics Inc has a 1 year low of $42.51 and a 1 year high of $69.81.
Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.38 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.41 by ($0.03). The firm had revenue of $29.39 million during the quarter, compared to the consensus estimate of $29.85 million. Anika Therapeutics had a return on equity of 11.91% and a net margin of 28.05%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.54 EPS. analysts expect that Anika Therapeutics Inc will post 1.57 earnings per share for the current year.
WARNING: “Metropolitan Life Insurance Co. NY Sells 5,276 Shares of Anika Therapeutics Inc (ANIK)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/22/metropolitan-life-insurance-co-ny-sells-5276-shares-of-anika-therapeutics-inc-anik.html.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.